An open study of oxcarbazepine combined with selective serotonin re-uptake inhibitor in treating outpatients with agitated depression
10.3760/cma.j.issn.1671-8925.2010.07.025
- VernacularTitle:奥卡西平联合选择性5-羟色胺再摄取抑制剂治疗激越性抑郁的开放性研究
- Author:
Yong-Chun MA
1
;
Zheng-Xin CHEN
;
Wei-Dong JIN
Author Information
1. 浙江省立同德医院
- Keywords:
Agitated depression;
Selective serotonin re-uptake inhibitor;
Oxcarbazepin
- From:
Chinese Journal of Neuromedicine
2010;09(7):744-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the efficacy and safety of oxcarbazepine combined with selective serotonin re-uptake inhibitor (SSRI) in the treatment of outpatients with agitated depression. Methods Thirty-two outpatients with agitated symptoms meeting CCMD-3 depression criteria were treated with oxcarbazepine combined with SSRI for 8 w: the dosage of oxcarbazepine changed dairy (1st and 2nd d, 0.3 g; 3rd d, 0.6 g; 7th and 8th, 1.2-1.5 g). The efficacy and side effects were assessed by Hamilton depression scale, Hamilton anxiety rating scale and Young manic-state rating scale. Results The mean dosage of oxcarbazepine in 32 patients was (1020±65) mg/d. Their mean effective rate and full remission rate 87.5% and 65.6%,respectively. The mean effective rate and full remission rate 1, 2, 4 and 8 w after the treatment were 28.1% (9/32) and 6.3% (2/32), 37.5% (12/32) and 12.5% (4/32), 46.9% (15/32) and 31.3% (10/32), and 90.6% (29/32) and 65.6% (21/32), respectively. The scores of the above scales 1, 2, 4 and 8 w after the treatment were significantly different with those before the treatment (P<0.05). Phase inversion was not found in these 32 patients. Conclusion The oxcarbazepine combined with SSRI maybe one of the better ways in the treatment of patients with agitated depression.
